SAN DIEGO, Oct. 20, 2023 (GLOBE NEWSWIRE) — DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial-stage biopharmaceutical company, today announced that the compensation committee of the board of directors approved the grant of a stock option on October 16, 2023, to purchase an aggregate of 151,416 shares of common stock to…Read More
DMK Pharmaceuticals Corporation DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635c4
